Incyte | INCY - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agenus USD 14.67M 1.35M 2026-03
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 247M 7M 2026-06
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
MacroGenics USD 4.89M 1.55M 2026-03
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06
Novartis USD 281M 8M 2025-09
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12